methyl 2-(tert-butoxycarbonylamino)propanoate | 112392-66-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl 2-(tert-butoxycarbonylamino)propanoate
• 英文别名: Methyl 2-{[(tert-butoxy)carbonyl]amino}propanoate；methyl 2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate
• CAS: 112392-66-2
• 化学式: C₉H₁₇NO₄
• 分子量: 203.238
• InChiKey: GJDICGOCZGRDFM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 2-(tert-butoxycarbonylamino)propanoate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 DL-丙氨酸甲酯盐酸盐
  参考文献：
  名称：

  6-Hydrazinopurine 2′-methyl ribonucleosides and their 5′-monophosphate prodrugs as potent hepatitis C virus inhibitors

  摘要：

  A series of 6-hydrazinopurine 2 '-methyl ribonucleosides was synthesized and tested for its inhibitory activity against the hepatitis C virus (HCV). The lack of antiviral activity of these nucleosides was associated with a poor affinity for adenosine kinase, which prompted us to synthesize several of their 5 '-monophosphate prodrugs. Some of these prodrugs exhibited more than 1000-fold improvement in anti-HCV activity when compared to their parent nucleosides (EC50 of 24 mu M vs 92 mu M for the parent). (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.02.029
• 作为产物：
  描述：

  N-叔丁氧羰基-L-丙氨酸 在 potassium carbonate 、 硫酸二甲酯 作用下， 以 甲醇 、 二氯甲烷 、 丙酮 为溶剂， 生成 methyl 2-(tert-butoxycarbonylamino)propanoate
  参考文献：
  名称：

  Hydantoin derivatives, salts thereof and maillard reaction inhibitors comprising the same

  摘要：

  公开号：

  EP0595183B1

文献信息

• [EN] 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH<br/>[FR] 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES COMME INHIBITEURS D'IDH MUTANTE
  申请人：NOVARTIS AG

  公开号：WO2014141104A1

  公开（公告）日：2014-09-18

  The invention is directed to a formula (I), or a pharmamceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

  这项发明涉及一种式(I)的配方，或其药用可接受的盐，其中R1、R2a、R2b和R3-R7在此处。该发明还涉及含有式(I)化合物的组合物，以及在抑制具有新型活性的突变IDH蛋白中使用这种化合物的用途。该发明还涉及在治疗与这种突变IDH蛋白相关的疾病或紊乱中使用式(I)化合物，包括但不限于细胞增殖紊乱，如癌症。
• Manganese Catalyzed Direct Amidation of Esters with Amines
  作者：Zhengqiang Fu、Xinghua Wang、Sheng Tao、Qingqing Bu、Donghui Wei、Ning Liu

  DOI：10.1021/acs.joc.0c02478

  日期：2021.2.5

  metal catalyzed amidations remains a challenge. Here, a manganese(I)-catalyzed method for the direct synthesis of amides from a various number of esters and amines is reported with unprecedented substrate scope using a low catalyst loading. A wide range of aromatic, aliphatic, and heterocyclic esters, even in fatty acid esters, reacted with a diverse range of primary aryl amines, primary alkyl amines

  酯与胺的过渡金属催化的酰胺键形成反应已被开发为克服传统方法的缺点的先进方法。在过渡金属催化的酰胺化反应中底物的广泛应用仍然是一个挑战。在此，报道了锰（I）催化的方法，其由多种酯和胺直接合成酰胺，具有低催化剂载量，具有无与伦比的底物范围。甚至在脂肪酸酯中，各种各样的芳族，脂族和杂环酯也与各种各样的伯芳基胺，伯烷基胺和仲烷基胺反应形成酰胺。值得注意的是，该方法提供了由脂肪酸酯和胺形成过渡金属催化的酰胺键形成反应的第一个例子。
• [EN] USE OF ICRF-193 DERIVATIVES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEREOF FOR THE PREVENTION OF CHRONIC CUMULATIVE CARDIOTOXICITY CAUSED BY THERAPY WITH ANTHRACYCLINE ANTICANCER DRUGS<br/>[FR] UTILISATION DE DÉRIVÉS DE L'ICRF-193 ET PRÉPARATIONS PHARMACEUTIQUES LES CONTENANT POUR LA PRÉVENTION DE LA CARDIOTOXICITÉ CUMULATIVE CHRONIQUE PROVOQUÉE PAR UNE THÉRAPIE AVEC DES MÉDICAMENTS ANTICANCÉREUX À BASE D'ANTHRACYCLINE
  申请人：UNIV KARLOVA

  公开号：WO2021144746A1

  公开（公告）日：2021-07-22

  Cardioprotective compounds based on analogues of the compound ICRF-193 of general formula I wherein R1 = H, 2-R2-2-aminoacetoxymethyl wherein R2 is selected from the group consisting of H, a C1-C6 alkyl or a branched alkyl of benzyl. These compounds can be produced by simple syntheses and are characterized with low toxicity and high effectiveness of protection of the heart against chronic cumulative cardiotoxicity caused by anthracycline anticancer therapy. The invention provides also a pharmaceutical preparation comprising the compound of general formula (I) as an active ingredient as well as use of this compound for the manufacture of a medicament for the prevention of chronic cumulative cardiotoxicity caused by therapy with anthracycline anticancer drugs.

  基于通式I的化合物ICRF-193的类似物的心脏保护化合物，其中R1 = H，2-R2-2-氨基乙氧甲基，其中R2选自H、C1-C6烷基或苄基的群。这些化合物可以通过简单的合成方法制备，并具有低毒性和高效保护心脏免受蒽环类抗癌治疗引起的慢性累积心脏毒性的特性。该发明还提供了一种包含通式(I)化合物作为活性成分的药物制剂，以及利用该化合物制造用于预防蒽环类抗癌药物治疗引起的慢性累积心脏毒性的药物的用途。
• [EN] PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES<br/>[FR] INHIBITEURS DE JAK3 DE TYPE PYRROLOPYRIDAZINE ET LEUR UTILISATION POUR TRAITER LES MALADIES INFLAMMATOIRES ET AUTO-IMMUNES
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2012125887A1

  公开（公告）日：2012-09-20

  Disclosed are compounds of formula (I) and pharmaceutically acceptable salts thereof. The compounds of formula (I) inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.

  揭示了式（I）的化合物及其药用盐。式（I）的化合物抑制JAK3的酪氨酸激酶活性，因此它们可用于治疗炎症和自身免疫性疾病。
• ANTIBIOTIC OLIGOPEPTIDE MIMETICS
  申请人：BIOXINESS PHARMACEUTICALS, INC.

  公开号：US20180340008A1

  公开（公告）日：2018-11-29

  Disclosed are amino acid mimetics that possess antibiotic properties in prokaryotic cells. These mimetics are coupled to one or more optionally substituted amino acids provided that at least one of the amino acids is an optionally substituted amino acid selected from the group consisting of phenylglycine, tryptophan, phenylalanine, histidine, and tyrosine.

  揭示了在原核细胞中具有抗生素特性的氨基酸类似物。这些类似物与一个或多个可选择取代的氨基酸偶联，其中至少一个氨基酸是从苯基甘氨酸、色氨酸、苯丙氨酸、组氨酸和酪氨酸所组成的群中选择的可选择取代的氨基酸。

表征谱图